Fingolimod is approved for the treatment of relapsing–remitting multiple sclerosis (MS), and evidence suggests that it has neuroprotective effects. The recent INFORMS phase III trial in primary progressive MS demonstrated no beneficial effects of fingolimod on disability progression or whole-brain atrophy, but provides important information for future therapeutic development.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Scientific Reports Open Access 07 April 2017
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387, 12–18 (2016).
Mahad, D. H., Trapp, B. D. & Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14, 183–193 (2015).
Wolinsky, J. S. et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 61, 14–24 (2007).
Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460–471 (2009).
Ontaneda, D., Fox, R. J. & Chataway, J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 14, 208–223 (2015).
Montalban, X. et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis — results of the placebo-controlled, double-blind, phase III ORATORIO study (abstract 228). Mult. Scler. 23 (Suppl. 11), 780–781 (2015).
Cohen, J. A. & Chun, J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 69, 759–777 (2011).
Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010).
Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355, 1124–1140 (2006).
Calabresi, P. A. et al. Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13, 545–556 (2014).
A.L.S. is supported by a National Multiple Sclerosis Society Sylvia Lawry Physician Fellowship Award (FP 17117-A-2).
A.L.S. has received speaking fees from Genzyme. J.A.C. has received personal compensation for consulting for Genentech, Genzyme, Novartis and Receptos, and speaking fees from Teva.
About this article
Cite this article
Smith, A., Cohen, J. Fingolimod failure in progressive MS INFORMS future trials. Nat Rev Neurol 12, 253–254 (2016). https://doi.org/10.1038/nrneurol.2016.37
This article is cited by
Scientific Reports (2017)